Literature DB >> 8607505

A study of eight medical centers of the safety and clinical efficacy of esophagogastroduodenoscopy in 83 pregnant females with follow-up of fetal outcome with comparison control groups.

M S Cappell1, V J Colon, O A Sidhom.   

Abstract

OBJECTIVES: To analyze risks versus benefits of esophagogastroduodenoscopy (EGD) during pregnancy to the fetus and pregnant female.
METHODS: Retrospective study of 83 consecutive pregnant patients who underwent EGD admitted to eight university teaching hospitals during a study period of up to 14 yr, with follow-up of fetal outcome. Controls included: 48 pregnant females matched for EGD indications who did not undergo EGD (pregnant controls), 83 nonpregnant females undergoing EGD matched for age and EGD indication (EGD controls), and national pregnancy outcome rates (national controls).
RESULTS: EGD indications included acute GI bleeding in 37, vomiting and abdominal pain in 17, vomiting in 14, abdominal pain in 11, and other in four. The mean week of gestation was 19.8 +/ 8.9 EGD was diagnostic in 65 patients. The diagnostic yield of EGD was 95% for acute GI bleeding and ranged from 50 to 82% for the other indications (significantly different rates, odds ratio = 9.3, p < 0.001, odds ratio confidence interval = 2.22-45.5). Esophagitis was found in 62+ of patients with a diagnostic EGD. No significant endoscopic complications occurred. EGD did not induce labor. Excluding six voluntary abortions and three unknown pregnancy outcomes, 70 (95%) of 74 patients delivered healthy babies (pregnant control rate = 94%, national control rate = 98.4%, all not significant, Fisher's exact test). Moreover, the four poor outcomes (three stillbirths and one involuntary abortion) occurred in high risk pregnancies and were unrelated to EGD temporally or etiologically. No other infant had a congenital malformation noted in the neonatal nursery. Nine (12.7%) of the live born infants had a low birth weight (pregnant control rate = 8.5%, national control rate = 7.0%, all not significant, kappa 2). Mean Apgar scores of live born infants were 7.7 +/ 1.6 at 1 min and 9.0 +/ 0.6 at 5 min (pregnant control scores = 7.6 +/ 2.0 at 1 min and 8.5 +/ 1.1 at 5 min; national control mean scores = 8.0 +/ 1.4 at 1 min and 9.0 +/ 0.9 at 5 min; all not significant, Student's t test). In three cases with fetal cardiac monitoring, EGD did not induce abnormal fetal heart rates (preendoscopy rate = 143.3 +/ 5.8 beats/min, postendoscopy rate = 148.0 +/ 10.6 beats/min).
CONCLUSIONS: In this study, EGD did not induce labor or result in congenital malformations. EGD is not contraindicated during pregnancy. EGD is beneficial in pregnant patients with upper GI bleeding.

Entities:  

Mesh:

Year:  1996        PMID: 8607505

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  15 in total

1.  Glutamine synthetase in newborn mice homozygous for lethal albino alleles.

Authors:  S Gluecksohn-Waelsch; M B Schiffman
Journal:  Dev Biol       Date:  1975-08       Impact factor: 3.582

Review 2.  Risks versus benefits of gastrointestinal endoscopy during pregnancy.

Authors:  Mitchell S Cappell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-04       Impact factor: 46.802

Review 3.  Nausea and vomiting of pregnancy.

Authors:  Noel M Lee; Sumona Saha
Journal:  Gastroenterol Clin North Am       Date:  2011-06       Impact factor: 3.806

4.  A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups.

Authors:  M S Cappell; V J Colon; O A Sidhom
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 5.  Gastrointestinal endoscopy in pregnancy.

Authors:  Nurten Savas
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

Review 6.  ERCP in the management of choledocholithiasis in pregnancy.

Authors:  Calvin H Y Chan; Robert A Enns
Journal:  Curr Gastroenterol Rep       Date:  2012-12

Review 7.  Are proton pump inhibitors safe during pregnancy and lactation? Evidence to date.

Authors:  Raj Majithia; David A Johnson
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

Review 8.  Inflammatory bowel disease and pregnancy: evidence, uncertainty and patient decision-making.

Authors:  Flavio M Habal; Varun Kapila
Journal:  Can J Gastroenterol       Date:  2009-01       Impact factor: 3.522

Review 9.  Treating gastro-oesophageal reflux disease during pregnancy and lactation: what are the safest therapy options?

Authors:  C N Broussard; J E Richter
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

Review 10.  Gastrointestinal endoscopy in the pregnant woman.

Authors:  David Friedel; Stavros Stavropoulos; Shahzad Iqbal; Mitchell S Cappell
Journal:  World J Gastrointest Endosc       Date:  2014-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.